303-A College Road East,
Princeton, New Jersey 08540
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset’s research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication.
Pharmasset was acquired by Gilead Sciences on November 21, 2011.
Join Mergr to view all 163 acquisitions of life science companies in 2011, including 18 acquisitions by private equity firms, and 145 by strategics.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Pharmasset.
No obligation. Cancel anytime.